VivoSeq
Gastroenterology

Lumbar Disc Herniation

7

Pipeline Programs

4

Active Trials

3

Companies Involved

Lumbar Disc Herniation is an early-stage landscape with 7 programs across 3 companies. The most active players are Sanofi, Stayble Therapeutics, Intrinsic Therapeutics. 1 program is in Phase 3.

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

15/100

Mech. Concentration

100/100

Completion Rate

92/100

Attrition Rate

6/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Modality Breakdown

88%

Small molecule

7 of 8 classified programs — the dominant modality here.

13%ALL OTHERSProtein / enzyme113%

Small molecule leads; the ring shows all 8 classified programs, each share of the total. Modality classified for 82% of 11 pipeline programs.

Trial Status

17

clinical trials

Completed12 · 71%
Recruiting2 · 12%
Not yet recruiting2 · 12%
Withdrawn1 · 6%

Trial Activity

17 trials

STA363 in the Treatment of Lumbar Disc Herniation
Completed·SStayble Therapeutics·Phase 1·NCT06022263·25 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)